Abstract | BACKGROUND: METHODS: 1010 newly diagnosed consecutive patients were included in the registry between February 2015 and September 2016. Diagnosis was confirmed by right heart catheterisation, ventilation-perfusion lung scan, computerised pulmonary angiography and/or invasive pulmonary angiography after at least 3 months on anticoagulation. RESULTS: Overall, 649 patients (64.3%) were considered for PEA, 193 (19.1%) for BPA, 20 (2.0%) for both PEA and BPA, and 148 (14.7%) for PAH therapy only. Reasons for PEA inoperability were technical inaccessibility (n=235), comorbidities (n=63) and patient refusal (n=44). In Europe and America and other countries (AAO), 72% of patients were deemed suitable for PEA, whereas in Japan, 70% of patients were offered BPA as first choice. Sex was evenly balanced, except in Japan where 75% of patients were female. A history of acute pulmonary embolism was reported for 65.6% of patients. At least one PAH therapy was initiated in 35.8% of patients (26.2% of PEA candidates, 54.5% of BPA candidates and 54.1% of those not eligible for either PEA or BPA). At the time of analysis, 39 patients (3.9%) had died of pulmonary hypertension-related causes (3.5% after PEA and 1.8% after BPA). CONCLUSIONS: The registry revealed noticeable differences in patient characteristics (rates of pulmonary embolism and sex) and therapeutic approaches in Japan compared with Europe and AAO.
|
Authors | Stefan Guth, Andrea M D'Armini, Marion Delcroix, Kazuhiko Nakayama, Elie Fadel, Stephen P Hoole, David P Jenkins, David G Kiely, Nick H Kim, Irene M Lang, Michael M Madani, Hiromi Matsubara, Aiko Ogawa, Jaquelina S Ota-Arakaki, Rozenn Quarck, Roela Sadushi-Kolici, Gérald Simonneau, Christoph B Wiedenroth, Bedrettin Yildizeli, Eckhard Mayer, Joanna Pepke-Zaba |
Journal | ERJ open research
(ERJ Open Res)
Vol. 7
Issue 3
(Jul 2021)
ISSN: 2312-0541 [Print] England |
PMID | 34409094
(Publication Type: Journal Article)
|
Copyright | Copyright ©The authors 2021. |